

Roland E Schmieder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8309246/publications.pdf>

Version: 2024-02-01

345
papers

46,225
citations

7551

77
h-index

1895

208
g-index

369
all docs

369
docs citations

369
times ranked

31328
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	1.0	6,826
2	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
3	2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension, 2013, 31, 1281-1357.	0.3	4,251
4	2018 ESC/ESH Guidelines for the management of arterial hypertension. Journal of Hypertension, 2018, 36, 1953-2041.	0.3	2,129
5	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2) Tj ETQq1 1 0.784314 rgBT /Ov	6.3	2,002
6	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	6.3	1,442
7	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension, 2009, 27, 2121-2158.	0.3	1,236
8	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1751-1762.	0.3	1,152
9	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Journal of Hypertension, 2013, 31, 1925-1938.	0.3	789
10	A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. American Journal of Medicine, 2003, 115, 41-46.	0.6	686
11	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, The, 2017, 390, 2160-2170.	6.3	597
12	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet, The, 2018, 391, 2346-2355.	6.3	597
13	Renin-angiotensin system and cardiovascular risk. Lancet, The, 2007, 369, 1208-1219.	6.3	583
14	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Pressure, 2014, 23, 3-16.	0.7	565
15	Preeclampsia â€” A State of Sympathetic Overactivity. New England Journal of Medicine, 1996, 335, 1480-1485.	13.9	526
16	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, The, 2018, 391, 2335-2345.	6.3	526
17	Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients. Circulation, 2005, 111, 1012-1018.	1.6	485
18	Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events. JAMA - Journal of the American Medical Association, 2011, 306, 2229-38.	3.8	471

#	ARTICLE	IF	CITATIONS
19	Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. <i>Circulation</i> , 2012, 126, 2976-2982.	1.6	420
20	Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2299-2307.	1.2	374
21	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2013, 22, 193-278.	0.7	355
22	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Blood Pressure</i> , 2009, 18, 308-347.	0.7	351
23	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 1444-1451.	6.3	351
24	²³ Na Magnetic Resonance Imaging-Determined Tissue Sodium in Healthy Subjects and Hypertensive Patients. <i>Hypertension</i> , 2013, 61, 635-640.	1.3	332
25	Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension. <i>Hypertension</i> , 2012, 60, 419-424.	1.3	289
26	Dietary salt intake. A determinant of cardiac involvement in essential hypertension.. <i>Circulation</i> , 1988, 78, 951-956.	1.6	271
27	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , 2017, 389, 2226-2237.	6.3	263
28	Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension. <i>Circulation</i> , 2013, 128, 132-140.	1.6	240
29	Increased Bioavailability of Nitric Oxide After Lipid-Lowering Therapy in Hypercholesterolemic Patients. <i>Circulation</i> , 1998, 98, 211-216.	1.6	234
30	Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1353-1364.	3.0	234
31	New Approaches in the Treatment of Hypertension. <i>Circulation Research</i> , 2015, 116, 1074-1095.	2.0	233
32	ESH Position Paper. <i>Journal of Hypertension</i> , 2012, 30, 837-841.	0.3	227
33	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPPLICITY HTN-2 randomized clinical trial. <i>European Heart Journal</i> , 2014, 35, 1752-1759.	1.0	227
34	²³ Na Magnetic Resonance Imaging of Tissue Sodium. <i>Hypertension</i> , 2012, 59, 167-172.	1.3	223
35	Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive Patients. <i>American Journal of Hypertension</i> , 2008, 21, 500-508.	1.0	206
36	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6.3	6.3	197

#	ARTICLE	IF	CITATIONS
37	Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. <i>Journal of Hypertension</i> , 2008, 26, 403-411.	0.3	190
38	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. <i>European Heart Journal</i> , 2019, 40, 3474-3482.	1.0	189
39	Accuracy of Cuff-Measured Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 572-586.	1.2	186
40	The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League. <i>Journal of Hypertension</i> , 2008, 26, 1487-1496.	0.3	182
41	Hypertension and atrial fibrillation. <i>Journal of Hypertension</i> , 2012, 30, 239-252.	0.3	177
42	First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension. <i>Hypertension</i> , 2015, 65, 766-774.	1.3	172
43	Meta-analysis. Update on reversal of left ventricular hypertrophy in essential hypertension (a) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Transplantation, 1998, 13, 564-569.	0.4	168
44	Effect of Telmisartan on Renal Outcomes. <i>Annals of Internal Medicine</i> , 2009, 151, 1.	2.0	163
45	Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1867-1876.	3.0	157
46	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). <i>Circulation</i> , 2011, 124, 1727-1736.	1.6	156
47	Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. <i>Lancet, The</i> , 2015, 385, 1634-1641.	6.3	155
48	Salt and Hypertension: Is Salt Dietary Reduction Worth the Effort?. <i>American Journal of Medicine</i> , 2012, 125, 433-439.	0.6	154
49	SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. <i>Cardiovascular Diabetology</i> , 2018, 17, 5.	2.7	147
50	Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan: A Double-Blind, Randomized, Prospective Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3038-3045.	3.0	146
51	Impaired Endothelial Function of the Retinal Vasculature in Hypertensive Patients. <i>Stroke</i> , 2004, 35, 1289-1293.	1.0	145
52	Impaired endothelial function in arterial hypertension and hypercholesterolemia. <i>Journal of Hypertension</i> , 2000, 18, 363-374.	0.3	142
53	Increased Wall:Lumen Ratio of Retinal Arterioles in Male Patients With a History of a Cerebrovascular Event. <i>Hypertension</i> , 2007, 50, 623-629.	1.3	139
54	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2012, 30, 1047-1055.	0.3	134

#	ARTICLE	IF	CITATIONS
55	Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren. <i>Circulation</i> , 2009, 119, 417-425.	1.6	129
56	Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. <i>American Heart Journal</i> , 2005, 149, 473.e1-473.e10.	1.2	127
57	International Expert Consensus Statement. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2031-2045.	1.2	124
58	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2013, 168, 2214-2220.	0.8	122
59	Angiotensin II Related to Sodium Excretion Modulates Left Ventricular Structure in Human Essential Hypertension. <i>Circulation</i> , 1996, 94, 1304-1309.	1.6	120
60	Impact of Telmisartan Versus Ramipril on Renal Endothelial Function in Patients With Hypertension and Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 1351-1356.	4.3	119
61	Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1167-1169.	1.6	119
62	A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. <i>Cardiovascular Diabetology</i> , 2017, 16, 26.	2.7	115
63	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 6.3 194	0.784314	194
64	Rapid Nongenomic Effects of Aldosterone on Human Forearm Vasculature. <i>Hypertension</i> , 2003, 42, 156-160.	1.3	113
65	Beyond salt: lifestyle modifications and blood pressure. <i>European Heart Journal</i> , 2011, 32, 3081-3087.	1.0	111
66	Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension. <i>Hypertension</i> , 2015, 65, 193-199.	1.3	109
67	Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1261-1266.	0.3	103
68	End Organ Damage In Hypertension. <i>Deutsches A&#x0308;rztblatt International</i> , 2010, 107, 866-73.	0.6	102
69	Low-grade albuminuria and cardiovascular risk. <i>Clinical Research in Cardiology</i> , 2007, 96, 247-257.	1.5	99
70	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019, 139, 2542-2553.	1.6	97
71	Renal Denervation in Moderate Treatment-Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1880-1886.	1.2	93
72	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120â€“140) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 1.0 92 trials. <i>European Heart Journal</i> , 2018, 39, 3105-3114.	1.0	92

#	ARTICLE	IF	CITATIONS
73	Analysis of retinal arteriolar structure in never-treated patients with essential hypertension. Journal of Hypertension, 2008, 26, 1427-1434.	0.3	90
74	European Society of Hypertension position paper on renal denervation 2021. Journal of Hypertension, 2021, 39, 1733-1741.	0.3	88
75	Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. Journal of the American College of Cardiology, 2001, 37, 175-182.	1.2	84
76	Hypertension and the heart. Journal of Human Hypertension, 2000, 14, 597-604.	1.0	82
77	How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovascular Diabetology, 2019, 18, 44.	2.7	80
78	Renal Denervation in High-Risk Patients With Hypertension. Journal of the American College of Cardiology, 2020, 75, 2879-2888.	1.2	80
79	Assessment of endothelial function of the renal vasculature in human subjects. American Journal of Hypertension, 2002, 15, 3-9.	1.0	75
80	Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice, 2007, 61, 1461-1468.	0.8	75
81	Renal Denervation Update From the International Sympathetic Nervous System Summit. Journal of the American College of Cardiology, 2019, 73, 3006-3017.	1.2	74
82	Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension.. Journal of the American Society of Nephrology: JASN, 1997, 8, 893-900.	3.0	74
83	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. JACC: Cardiovascular Interventions, 2020, 13, 471-484.	1.1	73
84	Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome. Nephrology Dialysis Transplantation, 2010, 25, 1126-1133.	0.4	70
85	The role of non-haemodynamic factors of the genesis of LVH. Nephrology Dialysis Transplantation, 2005, 20, 2610-2612.	0.4	69
86	Improvement of albuminuria after renal denervation. International Journal of Cardiology, 2014, 173, 311-315.	0.8	69
87	Central Pulse Pressure Is an Independent Determinant of Vascular Remodeling in the Retinal Circulation. Hypertension, 2013, 61, 1340-1345.	1.3	68
88	New developments in the pathogenesis of obesity-induced hypertension. Journal of Hypertension, 2015, 33, 1499-1508.	0.3	68
89	Does obesity influence early target organ damage in hypertensive patients?. Circulation, 1993, 87, 1482-1488.	1.6	67
90	Wall-to-Lumen Ratio of Retinal Arterioles and Arteriole-to-Venule Ratio of Retinal Vessels in Patients with Cerebrovascular Damage. , 2009, 50, 4351.		67

#	ARTICLE	IF	CITATIONS
91	Cardiac performance after reduction of myocardial hypertrophy. American Journal of Medicine, 1989, 87, 22-27.	0.6	65
92	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient. Journal of Hypertension, 2014, 32, 1888-1897.	0.3	65
93	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. American Heart Journal, 2018, 195, 115-129.	1.2	64
94	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. Journal of the American College of Cardiology, 2021, 77, 2909-2919.	1.2	63
95	Wall-to-Lumen Ratio of Retinal Arterioles as a Tool to Assess Vascular Changes. Hypertension, 2009, 54, 384-387.	1.3	61
96	Renal Denervation for Treating Hypertension. JACC: Cardiovascular Interventions, 2019, 12, 1095-1105.	1.1	61
97	Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention, 2013, 9, R58-R66.	1.4	60
98	Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach Focus on treatment by antihypertensive agents. American Journal of Hypertension, 1998, 11, 1394-1404.	1.0	59
99	New software analyses increase the reliability of measurements of retinal arterioles morphology by scanning laser Doppler flowmetry in humans. Journal of Hypertension, 2011, 29, 777-782.	0.3	59
100	Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients. European Heart Journal Cardiovascular Imaging, 2017, 18, 945-960.	0.5	59
101	Remodeling of Retinal Small Arteries in Hypertension. American Journal of Hypertension, 2011, 24, 1267-1273.	1.0	56
102	Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovascular Diabetology, 2014, 13, 19.	2.7	56
103	Rationale and design of a large registry on renal denervation: the Global SYMPPLICITY registry. EuroIntervention, 2013, 9, 484-492.	1.4	56
104	Wilder's principle: pre-treatment value determines post-treatment response. European Heart Journal, 2015, 36, 576-579.	1.0	55
105	Medication adherence in hypertension. Journal of Hypertension, 2020, 38, 579-587.	0.3	55
106	Accelerated decline in renal perfusion with aging in essential hypertension.. Hypertension, 1994, 23, 351-357.	1.3	54
107	Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrology Dialysis Transplantation, 2007, 23, 1346-1354.	0.4	54
108	Adherence to Antihypertensive Medication in Treatment-Resistant Hypertension Undergoing Renal Denervation. Journal of the American Heart Association, 2016, 5, .	1.6	54

#	ARTICLE	IF	CITATIONS
109	Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. <i>Journal of Hypertension</i> , 2009, 27, 673-679.	0.3	53
110	Why in 2016 are patients with hypertension not 100% controlled? A call to action. <i>Journal of Hypertension</i> , 2016, 34, 1480-1488.	0.3	52
111	Salt. A perpetrator of hypertensive target organ disease?. <i>Archives of Internal Medicine</i> , 1997, 157, 2449-2452.	4.3	52
112	Vascular and Renal Hemodynamic Changes after Renal Denervation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1195-1201.	2.2	51
113	Obesity as a determinant for response to antihypertensive treatment.. <i>BMJ: British Medical Journal</i> , 1993, 307, 537-540.	2.4	47
114	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , 2019, 40, 2032-2043.	1.0	47
115	Patient preference for therapies in hypertension: a cross-sectional survey of German patients. <i>Clinical Research in Cardiology</i> , 2019, 108, 1331-1342.	1.5	47
116	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2922-2933.	1.1	47
117	The role of nitric oxide in the regulation of glomerular haemodynamics in humans. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1392-1397.	0.4	46
118	What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. <i>EuroIntervention</i> , 2014, 9, 1027-1035.	1.4	46
119	Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension ¹ See Editorial by Noris and Remuzzi, p. 1545.. <i>Kidney International</i> , 2002, 61, 1462-1468.	2.6	45
120	Renal resistive index in addition to low-grade albuminuria complements screening for target organ damage in therapy-resistant hypertension. <i>Journal of Hypertension</i> , 2010, 28, 608-614.	0.3	45
121	Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. <i>EuroIntervention</i> , 2015, 11, 110-116.	1.4	45
122	Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension. <i>Hypertension</i> , 2017, 70, 1099-1105.	1.3	44
123	Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. <i>Journal of Hypertension</i> , 2009, 27, 1493-1501.	0.3	43
124	Wall-to-lumen ratio of retinal arterioles is related with urinary albumin excretion and altered vascular reactivity to infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine. <i>Journal of Hypertension</i> , 2009, 27, 2201-2208.	0.3	42
125	Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2015, 104, 672-678.	1.5	42
126	Diagnosis and treatment of arterial hypertension 2021. <i>Kidney International</i> , 2022, 101, 36-46.	2.6	41

#	ARTICLE	IF	CITATIONS
127	Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. <i>Diabetologia</i> , 2014, 57, 2019-2029.	2.9	40
128	Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension – WAVE IV. <i>Journal of Hypertension</i> , 2018, 36, 680-689.	0.3	40
129	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. <i>Journal of Hypertension</i> , 2014, 32, 1741-1750.	0.3	39
130	European Society of Hypertension position paper on renal denervation 2018. <i>Journal of Hypertension</i> , 2018, 36, 2042-2048.	0.3	39
131	Tonic Postganglionic Sympathetic Inhibition Induced by Afferent Renal Nerves?. <i>Hypertension</i> , 2012, 59, 467-476.	1.3	38
132	Renal Vascular Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus. <i>American Journal of Kidney Diseases</i> , 2009, 53, 281-289.	2.1	37
133	Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 271-279.	3.1	37
134	Physician attitudes to blood pressure control. <i>Journal of Hypertension</i> , 2011, 29, 1633-1640.	0.3	37
135	Disproportional Decrease in Office Blood Pressure Compared With 24-Hour Ambulatory Blood Pressure With Antihypertensive Treatment. <i>Hypertension</i> , 2014, 64, 1067-1072.	1.3	37
136	Renal Denervation in a Hypertensive Patient With End-Stage Renal Disease and Small Arteries: A Direction for Future Research. <i>Journal of Clinical Hypertension</i> , 2012, 14, 799-801.	1.0	35
137	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , 2020, 41, 231-238.	1.0	35
138	Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. <i>American Journal of Hypertension</i> , 2003, 16, 1030-1035.	1.0	34
139	Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2513-2518.	0.4	34
140	Blood Pressure Control in Patients With Comorbidities. <i>Journal of Clinical Hypertension</i> , 2008, 10, 624-631.	1.0	34
141	Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 572-581.	1.4	33
142	Retinal capillary rarefaction in patients with untreated mild-moderate hypertension. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 300.	0.7	33
143	MASKed-unconTrolled hypERTension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. <i>BMJ Open</i> , 2018, 8, e021038.	0.8	33
144	Confounding Factors in Renal Denervation Trials. <i>Hypertension</i> , 2020, 76, 1410-1417.	1.3	33

#	ARTICLE	IF	CITATIONS
145	Impact of dietary sodium intake on left ventricular diastolic filling in early essential hypertension. <i>European Heart Journal</i> , 1998, 19, 951-958.	1.0	32
146	Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. <i>Hypertension</i> , 2017, 70, 938-948.	1.3	31
147	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 10-25.	0.4	30
148	Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. <i>Cardiovascular Diabetology</i> , 2021, 20, 219.	2.7	30
149	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. <i>Clinical Science</i> , 2000, 99, 293-302.	1.8	29
150	Externally Delivered Focused Ultrasound for Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1292-1299.	1.1	29
151	Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2018, 72, 929-936.	1.3	29
152	Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. <i>Journal of Hypertension</i> , 2021, 39, 162-168.	0.3	29
153	Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. <i>Atherosclerosis</i> , 2008, 196, 704-711.	0.4	28
154	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020, 109, 289-302.	1.5	28
155	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
156	Impaired Sodium Excretion During Mental Stress in Mild Essential Hypertension. <i>Hypertension</i> , 2001, 37, 923-927.	1.3	27
157	Local application of tropicamide 0.5% reduces retinal capillary blood flow. <i>Blood Pressure</i> , 2013, 22, 371-376.	0.7	27
158	Influence of Age on Upper Arm Cuff Blood Pressure Measurement. <i>Hypertension</i> , 2020, 75, 844-850.	1.3	27
159	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1028-1038.	1.2	27
160	Stress response pattern in obesity and systemic hypertension. <i>American Journal of Cardiology</i> , 1992, 70, 1035-1039.	0.7	26
161	Renal denervation—implications for chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2014, 10, 305-313.	4.1	26
162	Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. <i>Journal of Hypertension</i> , 2016, 34, 393-396.	0.3	26

#	ARTICLE	IF	CITATIONS
163	Cocoa Flavanol Cardiovascular Effects Beyond Blood Pressure Reduction. <i>Journal of Clinical Hypertension</i> , 2016, 18, 352-358.	1.0	26
164	Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 129-135.	1.1	25
165	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. <i>American Journal of Hypertension</i> , 1999, 12, 418-422.	1.0	24
166	Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress. <i>Kidney International</i> , 2006, 70, 1177-1181.	2.6	24
167	Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. <i>Journal of Hypertension</i> , 2008, 26, 110-116.	0.3	24
168	Reduction in Basal Nitric Oxide Activity Causes Albuminuria. <i>Diabetes</i> , 2011, 60, 572-576.	0.3	24
169	Impaired Increase of Retinal Capillary Blood Flow to Flicker Light Exposure in Arterial Hypertension. <i>Hypertension</i> , 2012, 60, 871-876.	1.3	24
170	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Revista Española De Cardiología</i> , 2013, 66, 880.e1-880.e64.	0.6	24
171	Low dose eplerenone treatment decreases aortic stiffness in patients with resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 669-676.	1.0	24
172	Tissue sodium content in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 485-489.	1.2	24
173	Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis. <i>Clinical Science</i> , 2000, 98, 521-529.	1.8	23
174	Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	22
175	Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 56.	0.7	22
176	Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPPLICITY Registry with follow-up data of 3 years. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 304-310.	0.4	22
177	Antihypertensive therapy. To stop or not to stop?. <i>JAMA - Journal of the American Medical Association</i> , 1991, 265, 1566-1571.	3.8	22
178	Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2016, 11, e0162608.	1.1	22
179	Validation of a therapeutic scheme for the treatment of resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 498-504.	2.3	21
180	Renal denervation in hypertensive patients not on blood pressure lowering drugs. <i>Clinical Research in Cardiology</i> , 2016, 105, 755-762.	1.5	21

#	ARTICLE	IF	CITATIONS
181	Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. <i>Journal of Hypertension</i> , 2002, 20, 525-530.	0.3	20
182	Influence of blood flow on arteriolar wall-to-lumen ratio in the human retinal circulation in vivo. <i>Microvascular Research</i> , 2012, 83, 111-117.	1.1	20
183	Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 558-565.	1.8	20
184	Renal denervation: where do we stand and what is the relevance to the nephrologist?. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 638-644.	0.4	20
185	Renal protection with angiotensin receptor blockers: where do we stand. <i>Journal of Nephrology</i> , 2011, 24, 569-580.	0.9	20
186	L-Arginine-Induced Vasodilation of the Renal Vasculature Is Not Altered in Hypertensive Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2003, 26, 1836-1840.	4.3	19
187	Review of direct renin inhibition by aliskiren. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013, 14, 193-196.	1.0	19
188	Clinical situations associated with difficult-to-control hypertension. <i>Journal of Hypertension</i> , 2013, 31, S3-S8.	0.3	19
189	A guide for easy- and difficult-to-treat hypertension. <i>International Journal of Cardiology</i> , 2014, 172, 17-22.	0.8	19
190	Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension. <i>Journal of Hypertension</i> , 2016, 34, 2480-2486.	0.3	19
191	Reproducibility of Kidney Perfusion Measurements With Arterial Spin Labeling at 1.5 Tesla MRI Combined With Semiautomatic Segmentation for Differential Cortical and Medullary Assessment. <i>Medicine (United States)</i> , 2016, 95, e3083.	0.4	19
192	Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. <i>Diabetologia</i> , 2016, 59, 2579-2587.	2.9	19
193	Improvement in Retinal Capillary Rarefaction After Valsartan Treatment in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1112-1118.	1.0	19
194	Retinal capillary and arteriolar changes in patients with chronic kidney disease. <i>Microvascular Research</i> , 2018, 118, 121-127.	1.1	19
195	Individualised treatment targets in patients with type-2 diabetes and hypertension. <i>Cardiovascular Diabetology</i> , 2018, 17, 18.	2.7	19
196	Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. <i>Journal of Human Hypertension</i> , 2013, 27, 715-720.	1.0	18
197	How should data from SYMPLICITY HTN-3 be interpreted?. <i>Nature Reviews Cardiology</i> , 2014, 11, 375-376.	6.1	18
198	Clinical Impact of Patient Adherence to a Fixed-Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide. <i>Clinical Drug Investigation</i> , 2014, 34, 403-411.	1.1	18

#	ARTICLE	IF	CITATIONS
199	Renal denervation improves 24-hour central and peripheral blood pressures, arterial stiffness, and peripheral resistance. <i>Journal of Clinical Hypertension</i> , 2018, 20, 366-372.	1.0	18
200	Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids. <i>Theranostics</i> , 2020, 10, 8665-8676.	4.6	18
201	Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension. <i>Cardiology and Therapy</i> , 2020, 9, 19-34.	1.1	18
202	The role of statins in the treatment of the metabolic syndrome. <i>Current Hypertension Reports</i> , 2009, 11, 143-149.	1.5	17
203	Impact of renal denervation on tissue Na ⁺ content in treatment-resistant hypertension. <i>Clinical Research in Cardiology</i> , 2018, 107, 42-48.	1.5	17
204	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. <i>Hypertension</i> , 2019, 74, 244-249.	1.3	17
205	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 725-731.	1.5	17
206	Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. <i>Journal of Human Hypertension</i> , 2011, 25, 354-363.	1.0	16
207	Early vascular parameters in the micro- and macrocirculation in type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2018, 17, 128.	2.7	16
208	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. <i>American Heart Journal</i> , 2021, 239, 90-99.	1.2	16
209	Salt intake, blood pressure, and cardiovascular structure. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 425-432.	1.3	15
210	Effects of folic acid on renal endothelial function in patients with diabetic nephropathy: results from a randomized trial. <i>Clinical Science</i> , 2014, 127, 499-505.	1.8	15
211	Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin. <i>Clinical Research in Cardiology</i> , 2015, 104, 621-631.	1.5	15
212	Diuretic therapy and the risk for renal cell carcinoma. <i>Journal of Nephrology</i> , 2000, 13, 343-6.	0.9	15
213	High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. <i>Journal of Hypertension</i> , 2007, 25, 1627-1632.	0.3	14
214	Basal nitric oxide activity is an independent determinant of arteriolar structure in the human retinal circulation. <i>Journal of Hypertension</i> , 2011, 29, 123-129.	0.3	14
215	Rosuvastatin improves pulse wave reflection by restoring endothelial function. <i>Microvascular Research</i> , 2012, 84, 60-64.	1.1	14
216	25-Hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. <i>Clinical Research in Cardiology</i> , 2013, 102, 299-304.	1.5	14

#	ARTICLE	IF	CITATIONS
217	Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk. <i>Journal of Hypertension</i> , 2014, 32, 1334-1341.	0.3	14
218	Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. <i>Nephrology Dialysis Transplantation</i> , 2016, 33, gfw360.	0.4	14
219	Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 749-755.	0.7	14
220	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. <i>Journal of Human Hypertension</i> , 2022, 36, 629-639.	1.0	14
221	Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. <i>ESC Heart Failure</i> , 2021, 8, 5327-5337.	1.4	14
222	Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study. <i>Vascular Health and Risk Management</i> , 2012, 8, 177.	1.0	13
223	Poor Glycemic Control Is Related to Increased Nitric Oxide Activity Within the Renal Circulation of Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 4071-4075.	4.3	13
224	Effect of aliskiren on vascular remodelling in small retinal circulation. <i>Journal of Hypertension</i> , 2015, 33, 2491-2499.	0.3	13
225	Retinal vascular resistance in arterial hypertension. <i>Blood Pressure</i> , 2018, 27, 82-87.	0.7	13
226	Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	13
227	Relation of the first hypertension-associated event with medication, compliance and persistence in naïve hypertensive patients after initiating monotherapy. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2010, 48, 173-183.	0.3	13
228	Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. <i>Vascular Health and Risk Management</i> , 2010, 6, 803.	1.0	12
229	Expertise. <i>Journal of Hypertension</i> , 2017, 35, 1564-1566.	0.3	12
230	Telmisartan in incipient and overt diabetic renal disease. <i>Journal of Nephrology</i> , 2011, 24, 263-273.	0.9	12
231	Reversibility of the Effects of Aliskiren in the Renal Versus Systemic Circulation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 258-264.	2.2	11
232	Urinary Albumin Excretion From Spot Urine Samples Predict All-Cause and Stroke Mortality in Africans. <i>American Journal of Hypertension</i> , 2014, 27, 811-818.	1.0	11
233	First experience in analysing pulsatile retinal capillary flow and arteriolar structural parameters measured noninvasively in hypertensive patients. <i>Journal of Hypertension</i> , 2014, 32, 2246-2252.	0.3	11
234	Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6Âmonths results of the DIALOGUE registry. <i>BMC Endocrine Disorders</i> , 2015, 15, 23.	0.9	11

#	ARTICLE	IF	CITATIONS
235	Circadian rhythm and day to day variability of serum potassium concentration: a pilot study. <i>Journal of Nephrology</i> , 2015, 28, 165-172.	0.9	11
236	Early Signs of End-Organ Damage in Retinal Arterioles in Patients with Type 2 Diabetes Compared to Hypertensive Patients. <i>Microcirculation</i> , 2016, 23, 447-455.	1.0	11
237	Mid-Term Vascular Safety of Renal Denervation Assessed by Follow-up MR Imaging. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 426-432.	0.9	11
238	Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 364-371.	1.4	11
239	Changes in Stroke Volume After Renal Denervation. <i>Hypertension</i> , 2020, 75, 707-713.	1.3	11
240	Improved blood pressure control via a novel chronic disease management model of care in sub-Saharan Africa: Real-world program implementation results. <i>Journal of Clinical Hypertension</i> , 2021, 23, 785-792.	1.0	11
241	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2022, 21, 12.	2.7	11
242	Renal hemodynamic response to stress is influenced by ACE-inhibitors. <i>Clinical Nephrology</i> , 1994, 42, 381-8.	0.4	11
243	Effects of angiotensin converting enzyme inhibitor on renal haemodynamics during mental stress. <i>Journal of Hypertension</i> , 1996, 14, 1201-1207.	0.3	10
244	Not all left ventricular hypertrophy is created equal. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 2803-2805.	0.4	10
245	Effects of angiotensin II type 1-receptor blockade on retinal endothelial function. <i>Journal of Hypertension</i> , 2008, 26, 516-522.	0.3	10
246	Central arteriovenous anastomosis to treat resistant hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 8-15.	1.0	10
247	Effects of the nitric oxide synthase inhibitor ronopterin (VAS203) on renal function in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 900-907.	1.1	10
248	Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography. <i>Scientific Reports</i> , 2020, 10, 5255.	1.6	10
249	Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. <i>Cardiovascular Diabetology</i> , 2021, 20, 178.	2.7	10
250	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Hypertension</i> , 2022, 79, 1506-1514.	1.3	10
251	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. <i>Clinical Science</i> , 2000, 99, 293.	1.8	9
252	The potential role of prorenin in diabetic nephropathy. <i>Journal of Hypertension</i> , 2007, 25, 1323-1326.	0.3	9

#	ARTICLE	IF	CITATIONS
253	Cerebral Microangiopathy in Treatment-Resistant Hypertension. <i>Journal of Clinical Hypertension</i> , 2011, 13, 582-587.	1.0	9
254	Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry. <i>Journal of Clinical Hypertension</i> , 2015, 17, 947-953.	1.0	9
255	Aldosterone Antagonists and Renal Denervation. <i>Hypertension</i> , 2015, 65, 280-282.	1.3	9
256	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. <i>Free Radical Research</i> , 2017, 51, 14-23.	1.5	9
257	Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. <i>Journal of Hypertension</i> , 2020, 38, 2050-2058.	0.3	9
258	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , 2021, 39, 766-774.	0.3	9
259	Renal denervation in patients with chronic kidney disease: current evidence and future perspectives. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1089-1096.	0.4	9
260	Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an at1-receptor blocker in hypertensive patients. <i>American Journal of Hypertension</i> , 2004, 17, S108.	1.0	8
261	Olmesartan Improves Pulse Wave Velocity and Lowers Central Systolic Blood Pressure and Ambulatory Blood Pressure in Patients With Metabolic Syndrome. <i>Journal of Clinical Hypertension</i> , 2015, 17, 98-104.	1.0	8
262	The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes. <i>Medicine (United States)</i> , 2016, 95, e3122.	0.4	8
263	The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. <i>Journal of Hypertension</i> , 2016, 34, 2475-2479.	0.3	8
264	Scientific Data and Transparency of Conflict of Interest Are Important, Not Biased Editorial Without Facts. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2263.	1.1	8
265	Aortic stiffness is not only associated with structural but also functional parameters of retinal microcirculation. <i>Microvascular Research</i> , 2020, 129, 103974.	1.1	8
266	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010075.	1.4	8
267	Angiotensin Blockade to Reduce Microvascular Damage in Diabetes Mellitus. <i>Deutsches Arzteblatt International</i> , 2009, 106, 556-62.	0.6	7
268	Wall-to-lumen ratio of retinal arterioles. <i>Journal of Hypertension</i> , 2012, 30, 1108-1110.	0.3	7
269	EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 46.	0.7	7
270	Does Renal Artery Supply Indicate Treatment Success of Renal Denervation?. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 987-991.	0.9	7

#	ARTICLE	IF	CITATIONS
271	Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients: Prospective Case Series. <i>Hypertension</i> , 2013, 61, e17.	1.3	7
272	Optimizing blood pressure control in hypertension: The need to use ABPM. <i>Blood Pressure</i> , 2013, 22, 65-72.	0.7	7
273	Invasive Treatment of Resistant Hypertension: Present and Future. <i>Current Hypertension Reports</i> , 2014, 16, 488.	1.5	7
274	Renal Denervation for Resistant Hypertension: Past, Present, and Future. <i>Current Hypertension Reports</i> , 2015, 17, 65.	1.5	7
275	Non-invasive Renal Denervation: Update on External Ultrasound Approaches. <i>Current Hypertension Reports</i> , 2016, 18, 48.	1.5	7
276	Left Ventricular Structure in Patients With Mild-to-Moderate CKD—A Magnetic Resonance Imaging Study. <i>Kidney International Reports</i> , 2019, 4, 267-274.	0.4	7
277	3D-Visualization of Neurovascular Compression at the Ventrolateral Medulla in Patients with Arterial Hypertension. <i>Clinical Neuroradiology</i> , 2020, 31, 335-345.	1.0	7
278	Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia. <i>Journal of Nephrology</i> , 2009, 22, 675-81.	0.9	7
279	Change in Augmentation Index during NOS Inhibition, an Index of Basal NO Production, Is an Independent Determinant of Large-Artery Function. <i>Kidney and Blood Pressure Research</i> , 2010, 33, 343-351.	0.9	6
280	Lumen narrowing and increased wall to lumen ratio of retinal microcirculation are valuable biomarkers of hypertension-mediated cardiac damage. <i>Blood Pressure</i> , 2020, 29, 70-79.	0.7	6
281	Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 1562-1570.	1.4	6
282	Dependency of flow-mediated vasodilatation from basal nitric oxide activity. <i>Clinical Physiology and Functional Imaging</i> , 2021, 41, 310-316.	0.5	6
283	Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial. <i>Journal of Hypertension</i> , 2022, 40, 221-228.	0.3	6
284	Catheter-based Renal Sympathetic Denervation – Long-term Symplicity – Renal Denervation Clinical Evidence, New Data and Future Perspectives. <i>Interventional Cardiology Review</i> , 2013, 8, 118.	0.7	6
285	Ruling out secondary causes of hypertension. <i>EuroIntervention</i> , 2013, 9, R21-R28.	1.4	6
286	The influence of aircraft noise exposure on the systemic and renal haemodynamics. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 116-124.	0.8	6
287	Editorial comment: Renal denervation. <i>Hypertension Research</i> , 2022, 45, 241-243.	1.5	6
288	Risks Versus Benefits of Withdrawing Antihypertensive Therapy. <i>Drug Safety</i> , 1992, 7, 395-403.	1.4	5

#	ARTICLE	IF	CITATIONS
289	Pharmacokinetics of Valsartan in Hypertensive Patients on Long-Term Haemodialysis. <i>Clinical Drug Investigation</i> , 2001, 21, 59-66.	1.1	5
290	Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice – study rationale and protocol of DIALOGUE. <i>Cardiovascular Diabetology</i> , 2012, 11, 148.	2.7	5
291	Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes. <i>Journal of Hypertension</i> , 2014, 32, 2267-2276.	0.3	5
292	The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry. <i>Trials</i> , 2015, 16, 581.	0.7	5
293	Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 18.	1.5	5
294	Secretory Capacity of Pancreatic Beta-Cells Is Enhanced 6 Months After Renal Denervation in Hypertensive Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3372-3374.	1.2	5
295	Reference values of retinal microcirculation parameters derived from a population random sample. <i>Microvascular Research</i> , 2021, 134, 104117.	1.1	5
296	Novel approaches to management of hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 54-62.	1.0	5
297	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , 2021, 39, 1602-1610.	0.3	5
298	Association of Noise Annoyance with Measured Renal Hemodynamic Changes. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 323-330.	0.9	5
299	Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108055.	1.2	5
300	Tissue sodium content in hypertension and related organ damage. <i>Journal of Hypertension</i> , 2020, 38, 2363-2368.	0.3	5
301	When is discontinuation of antihypertensive therapy indicated?. <i>Cardiovascular Drugs and Therapy</i> , 1990, 4, 1487-1494.	1.3	4
302	Renal and Systemic Hemodynamics in Black and White Hypertensive Patients. <i>American Journal of Hypertension</i> , 1997, 10, 971-978.	1.0	4
303	Comment on ESH position paper. <i>Journal of Hypertension</i> , 2012, 30, 2443.	0.3	4
304	Haemoglobin and vascular function in the human retinal vascular bed. <i>Journal of Hypertension</i> , 2013, 31, 775-781.	0.3	4
305	Retinal microperfusion after renal denervation in treatment-resistant hypertensive patients. <i>Clinical Research in Cardiology</i> , 2015, 104, 782-789.	1.5	4
306	Expertise: No Longer a Sine Qua Non for Guideline Authors?. <i>Hypertension</i> , 2017, 70, 235-237.	1.3	4

#	ARTICLE	IF	CITATIONS
307	How to measure retinal microperfusion in patients with arterial hypertension. <i>Blood Pressure</i> , 2021, 30, 4-19.	0.7	4
308	Identifying Isolated Systolic Hypertension From Upper-Arm Cuff Blood Pressure Compared With Invasive Measurements. <i>Hypertension</i> , 2021, 77, 632-639.	1.3	4
309	Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. <i>Cardiovascular Diabetology</i> , 2022, 21, 4.	2.7	4
310	Hypertensive heart disease--significance of left ventricular hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , 1992, 20 Suppl 6, S50-5.	0.8	4
311	Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. <i>Vascular Health and Risk Management</i> , 2009, 5, 991.	1.0	3
312	Diagnosis and treatment of resistant hypertension. <i>Blood Pressure</i> , 2014, 23, 193-199.	0.7	3
313	Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment. <i>Journal of Hypertension</i> , 2020, 38, 1551-1558.	0.3	3
314	Detection of Changes in Renal Blood Flow Using Arterial Spin Labeling MRI. <i>American Journal of Nephrology</i> , 2021, 52, 69-75.	1.4	3
315	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. <i>Clinical Science</i> , 2000, 99, 293-302.	1.8	3
316	Current status of renal denervation in resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 414-416.	2.3	2
317	1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: Prospective 3A registry. <i>International Journal of Cardiology</i> , 2014, 176, 589-594.	0.8	2
318	Managing Treatment-Resistant Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 11-13.	1.0	2
319	Retinal Circulation in Arterial Disease. , 2015, , 397-414.		2
320	Two-Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non-Interventional Prospective Study. <i>Journal of Clinical Hypertension</i> , 2016, 18, 647-654.	1.0	2
321	Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1045-1053.	1.0	2
322	Increased Aldosterone Release During Head-Up Tilt in Early Primary Hypertension. <i>American Journal of Hypertension</i> , 2017, 30, 484-489.	1.0	2
323	Neurogenic substance P influences on action potential production in afferent neurons of the kidney?. <i>Pflügers Archiv European Journal of Physiology</i> , 2021, 473, 633-646.	1.3	2
324	Relationship Between Ubiquitin-Specific Peptidase 18 and Hypertension in Polish Adult Male Subjects: A Cross-Sectional Pilot Study. <i>Medical Science Monitor</i> , 2020, 26, e921919.	0.5	2

#	ARTICLE	IF	CITATIONS
325	Angiotensin II-Type 2 Receptor: Emerging Target for Cardiovascular Protection. American Journal of Hypertension, 2010, 23, 220-220.	1.0	1
326	Application of a central iliac arteriovenous coupler device in severe treatment-resistant hypertension. Journal of Hypertension, 2018, 36, 2471-2477.	0.3	1
327	Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation. American Journal of Hypertension, 2019, 33, 182-189.	1.0	1
328	Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure. ESC Heart Failure, 2021, 8, 1892-1900.	1.4	1
329	Response to: Cavagna et al The importance of considering cultural and environmental elements in an interventional model of care to fight hypertension in Africa. Journal of Clinical Hypertension, 2021, 23, 1271-1272.	1.0	1
330	Reversal of left ventricular hypertrophy: a desirable therapeutic goal?. Journal of Cardiovascular Pharmacology, 1990, 16 Suppl 6, S16-22.	0.8	1
331	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. American Journal of Hypertension, 1999, 12, 418-422.	1.0	0
332	Hypertension and Diabetes. Diabetes Care, 2009, 32, S294-S297.	4.3	0
333	Blood pressure and retinal small arteries. Journal of Hypertension, 2013, 31, 1946-1947.	0.3	0
334	Damage of Retinal Arterioles in Hypertension. , 2015, , 127-142.		0
335	The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry. Journal of Human Hypertension, 2015, 29, 316-323.	1.0	0
336	4325How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus?. European Heart Journal, 2018, 39, .	1.0	0
337	Assessment of Target Organ Damage. , 2018, , 189-199.		0
338	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. International Journal of Cardiology: Hypertension, 2019, 3, 100022.	2.2	0
339	Neurovascular Compression in Arterial Hypertension: Correlation of Clinical Data to 3D-Visualizations of MRI-Findings. Open Neuroimaging Journal, 2021, 14, 16-27.	0.2	0
340	The Optic Fundus and Retinal Circulation: New Technology for an Old Examination. , 2012, , 157-168.		0
341	Alternative Methods for Renal Denervation. Updates in Hypertension and Cardiovascular Protection, 2016, , 321-337.	0.1	0
342	Assessment of Retinal Arteriolar Morphology by SLDF. Updates in Hypertension and Cardiovascular Protection, 2020, , 27-41.	0.1	0

#	ARTICLE	IF	CITATIONS
343	The authors reply. <i>Kidney International</i> , 2022, 101, 830-832.	2.6	0
344	Nephroprotection by antihypertensive agents. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 24 Suppl 2, S55-64.	0.8	0
345	Obese hypertensive patients are less effectively treated than lean hypertensives. <i>Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension</i> , 1993, 11, S348-9.	0.1	0